BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed

We recently published 10 Big Names, Bigger Losses. BridgeBio Pharma Inc. (NASDAQ:BBIO) was one of the worst performers on Thursday.

BridgeBio fell by 15.24 percent on Thursday to close at $63.73 apiece, mirroring the broader market decline amid a highly pessimistic environment, while repositioning portfolios ahead of its earnings.

Based on its historical earnings reporting dates, BridgeBio Pharma Inc. (NASDAQ:BBIO) would release its financial and operating highlights for the fourth quarter and full-year 2025 periods on February 19, 2026.

Meanwhile, Thursday’s drop was primarily dampened by an overall market sentiment, as investors turned pessimistic following Bitcoin’s 50 percent decline from its all-time high of $126,000. This followed Treasury Secretary Scott Bessent’s reply to a House Committee hearing that he does not have the authority to bail out Bitcoin and other cryptocurrency assets.

In other news, BridgeBio Pharma Inc. (NASDAQ:BBIO) recently received a bullish outlook from Barclays and Morgan Stanley, both issuing the stock an “overweight” rating.

Barclays, for its part, gave the stock a $157 price target, while Morgan Stanley was more conservative at $96. Said prices represented an upside potential of 146 percent and 50.6 percent, respectively, from its latest closing price.

While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.